In hepatocellular carcinoma, cetuximab resistance is mediated via STAT3 activation, and therapies that combined inhibitors of STAT3 and EGFR exhibits enhanced growth inhibition in vitro29. Here, STAT3 is linked to hepatocellular carcinoma.